In vitro efficacy of 16 antimicrobial drugs against a large collection of β-lactamase-producing isolates of extraintestinal pathogenic Escherichia coli from dogs and cats
In vitro efficacy of 16 antimicrobial drugs against a large collection of β-lactamase-producing isolates of extraintestinal pathogenic Escherichia coli from dogs and cats
复制标题
DOI：
10.1099/jmm.0.000535
复制
发表时间：
2017-08-01
影响因子：
3
通讯作者：
Hikasa, Yoshiaki
中科院分区：
文献类型：
--
作者：
Shimizu, Takae;Harada, Kazuki;Hikasa, Yoshiaki
目的.本研究旨在评估候选抗菌剂对伴侣动物产超广谱β-内酰胺酶（ESBL）肠外致病性大肠杆菌（ExPEC）分离株的体外有效性。采用琼脂稀释法对90株犬、猫产ESBL的ExPEC进行了16种抗菌药物的敏感性试验。我们还确定了ESBLs和AmpC β-内酰胺酶的PCR和DNA测序这些菌株。所有分离株对美罗培南、替比培南和阿米卡星敏感，不同比例的分离株对拉氧头孢敏感（LMX，97.8%），磷霉素（FOM，97.8%），法罗培南（FPM，96.7%），呋喃妥因（NFT，96.7%），氟氧头孢（FMX，93.3%），哌拉西林/他唑巴坦（PTZ，92.2%），头孢美唑（CMZ，91.1%）、氯霉素（80.0%）、甲氧苄氨嘧啶/磺胺甲恶唑（64.4%）、阿莫西林/克拉维酸（63.3%）、头孢布烯（60.0%）、四环素（52.2%）和恩诺沙星（10.0%）。遗传分析显示，90株分离株中有83株（92.2%）CTX-M型基因呈阳性：CTX-M-14（n=26）、CTX-M-27（n=20）、CTX-M-55（n=17）、CTX-M-15（n=12）、CTX-M-2（n=5）、CTX-M-24（n =2）、CTX-M-104（n=2）和CTX-M-3（n=1）。8株菌株同时表达AmpC酶表型。本研究表明，PTZ、CMZ、LMX、AMK、FOM、FPM、NFT和FMX的敏感率与碳青霉烯类药物相似（> 90%），这意味着这些药物可替代碳青霉烯类药物治疗感染ExPEC产CTX-M型ESBLs的伴侣动物。需要对这些抗菌剂的有效使用进行进一步的体内研究。
Purpose. The aim of this study was to assess the in vitro efficacy of candidate antimicrobials against extended-spectrum beta-lactamase (ESBL)-producing isolates of extraintestinal pathogenic Escherichia coli (ExPEC) from companion animals.Methodology. A total of 90 ESBL-producing ExPEC isolates from dogs and cats were tested for susceptibility to 16 antimicrobials with the agar dilution method. We also identified the ESBLs and AmpC beta-lactamases of these isolates with PCR and DNA sequencing.Results/Key findings. All isolates were susceptible to meropenem, tebipenem and amikacin (AMK), and various proportions were susceptible to latamoxef (LMX, 97.8 %), fosfomycin (FOM, 97.8 %), faropenem (FPM, 96.7 %), nitrofurantoin (NFT, 96.7 %), flomoxef (FMX, 93.3 %), piperacillin/tazobactam (PTZ, 92.2 %), cefmetazole (CMZ, 91.1 %), chloramphenicol (80.0 %), trimethoprim/sulfamethoxazole (64.4 %), amoxicillin/clavulanic acid (63.3 %), ceftibuten (60.0 %), tetracycline (52.2 %) and enrofloxacin (10.0 %). A genetic analysis showed that 83 of the 90 (92.2 %) isolates were positive for CTX-M-type genes: CTX-M-14 (n=26), CTX-M-27 (n=20), CTX-M-55 (n=17), CTX-M-15 (n=12), CTX-M-2 (n=5), CTX-M-24 (n=2), CTX-M-104 (n=2) and CTX-M-3 (n=1). Eight isolates also expressed AmpC beta-lactamase phenotypes.Conclusion. This study demonstrates that the susceptibility rates to PTZ, CMZ, LMX, AMK, FOM, FPM, NFT and FMX were similar to those to carbapenems (>90 %), implying that these drugs are available alternatives to carbapenems for the treatment of companion animals infected with ExPEC-producing CTX-M-type ESBLs. Further in vivo studies of the effective use of these antimicrobials are required.